{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0024768\nAge: 49\nGender: Male\nSample ID: P-0024768-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Colon Adenocarcinoma\nSample Type: Primary\nTumor Purity: 20.0%\n=============\nDNA Variants:\nAPC c.4393_4394del (p.S1465Wfs*3) - in 13.00% of 474 reads\nAPC c.2932del (p.Q978Kfs*2) - in 12.00% of 395 reads\nATR c.1007G>T (p.R336L) - in 8.00% of 530 reads\nATRX c.6253C>T (p.R2085C) - in 21.00% of 262 reads\nBRAF c.1799T>A (p.V600E) - in 11.00% of 463 reads\nEP300 c.6970dup (p.H2324Pfs*55) - in 13.00% of 657 reads\nIKZF1 c.247C>T (p.R83*) - in 12.00% of 418 reads\nPIK3CA c.1633G>A (p.E545K) - in 12.00% of 393 reads\nRPTOR c.157G>T (p.D53Y) - in 10.00% of 420 reads\nTP53 c.524G>A (p.R175H) - in 17.00% of 542 reads\nZFHX3 c.4508_4513del (p.Q1503_S1504del) - in 12.00% of 572 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}"
}